Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Medtronic has received FDA approval for its SelectSecure Model 3830 cardiac lead to include left bundle branch area pacing, enhancing its conduction system pacing capabilities for patients with bradycardia. This innovative method mimics natural heart contraction, reducing complications associated with traditional pacing. The approval is based on evidence from over 20,000 patients, demonstrating a 92% procedural success rate and a low complication rate of 2.5%. Medtronic remains the only company with FDA-approved therapies for conduction system pacing, further solidifying its leading position in cardiac pacing technologies.
Medtronic plc (NYSE:MDT) announced a live webcast on November 7, 2022, at 5 p.m. CST, to discuss updates on its Coronary and Renal Denervation business during AHA 2022. The webcast will feature management remarks and present the 6-month results from the SPYRAL HTN-ON MED Randomized Trial. The ON MED data will be presented earlier that day, starting at 3:38 p.m. CST. A press release detailing the ON MED results will also be issued on the same date. A replay of the webcast will be available within 24 hours on Medtronic's investor relations page.
Summary not available.
Medtronic plc announced the release of its Fiscal Year 2022 Integrated Performance Report, emphasizing progress in health equity, workforce diversity, and environmental sustainability. Key highlights include:
- Investment of over $69 million for healthcare training, reaching 350,000 medical professionals.
- $2.7 billion invested in R&D.
- Reduction of greenhouse gas emissions intensity by 35%.
The report reflects Medtronic's commitment to its mission of improving health outcomes globally.
Medtronic plc (NYSE: MDT) announced the successful closing of a public offering totaling €3.5 billion in Senior Notes. This includes €500 million of 2.625% Notes due 2025, €1 billion of 3.000% Notes due 2028, €1 billion of 3.125% Notes due 2031, and €1 billion of 3.375% Notes due 2034. The net proceeds, approximately €3.47 billion, will be used to repay maturing senior notes and for general corporate purposes. The offering was managed by leading financial institutions, and all notes are guaranteed by Medtronic plc.
Ra Medical Systems, Inc. (RMED) announced the approval of three proposals at its Special Meeting of Stockholders held on September 20, 2022, including a crucial 1-for-50 reverse stock split. This measure is intended to maintain compliance with NYSE American listing standards, following a notice regarding low stock prices. Additionally, the Company plans to merge with Catheter Precision, which focuses on cardiac electrophysiology technology. The merger is anticipated to close by the end of 2022, pending shareholder approval and other conditions.
Medtronic plc (NYSE:MDT) has received FDA clearance for the LINQ II Insertable Cardiac Monitor (ICM), marking it the first and only device cleared for long-term monitoring in pediatric patients over the age of 2 with heart rhythm abnormalities. This innovation is significant for pediatric cardiologists, offering critical data for diagnosing and managing heart conditions.
The LINQ II ICM is compact, wireless, and features a battery life of up to 4.5 years. It incorporates AccuRhythm AI algorithms, reducing false alerts significantly while ensuring accurate monitoring.
Medtronic announced long-term results from the SYMPLICITY HTN-3 clinical trial at the TCT conference, showing significant reductions in blood pressure for patients undergoing renal denervation. Over three years, RDN patients experienced a 26.4 mm Hg reduction in office systolic blood pressure, compared to 5.7 mm Hg for the sham control group. The trial included 535 patients, with no long-term complications reported. These findings contribute to the growing evidence supporting the safety and efficacy of the Symplicity blood pressure procedure, which is approved for use in over 60 countries, though still investigational in the U.S.
Medtronic plc (NYSE:MDT) announced the pricing of €4.5 billion in senior notes by its subsidiary, Medtronic Luxco. This includes €500 million of 2.625% notes due 2025, €1 billion of 3.000% notes due 2028, €1 billion of 3.125% notes due 2031, and €1 billion of 3.375% notes due 2034. The proceeds will be used to repay existing notes and for general corporate purposes. The offering is set to close on September 21, 2022, pending customary conditions, with Barclays, BofA, Citigroup, and HSBC acting as joint book-running managers.
Ra Medical Systems (RMED) has announced a merger with Catheter Precision, a medical device company focusing on cardiac electrophysiology. This stock-for-stock reverse merger will result in Catheter Precision becoming a wholly owned subsidiary of Ra Medical. Catheter Precision's lead product, VIVO™, aims to improve treatment for ventricular arrhythmias, a significant market opportunity. The merger is expected to close by the end of 2022, pending shareholder approval. Post-merger, Catheter Precision stakeholders are projected to own 80% of the combined entity, enhancing growth potential in the cardiac market.